Citadel Advisors LLC boosted its stake in Coherus Biosciences Inc (NASDAQ:CHRS) by 819.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,772,241 shares of the biotechnology company’s stock after purchasing an additional 1,579,582 shares during the quarter. Citadel Advisors LLC’s holdings in Coherus Biosciences were worth $15,595,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Temasek Holdings Private Ltd acquired a new stake in Coherus Biosciences in the third quarter worth $87,524,000. Fox Run Management L.L.C. bought a new position in shares of Coherus Biosciences in the fourth quarter valued at $228,000. New York State Common Retirement Fund lifted its stake in shares of Coherus Biosciences by 32.1% in the second quarter. New York State Common Retirement Fund now owns 43,600 shares of the biotechnology company’s stock valued at $626,000 after buying an additional 10,599 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Coherus Biosciences by 13.8% in the second quarter. Northern Trust Corp now owns 464,056 shares of the biotechnology company’s stock valued at $6,660,000 after buying an additional 56,122 shares in the last quarter. Finally, Platinum Investment Management Ltd. bought a new position in shares of Coherus Biosciences in the third quarter valued at $1,457,000. Institutional investors and hedge funds own 82.46% of the company’s stock.
Coherus Biosciences Inc (CHRS) opened at $9.55 on Tuesday. Coherus Biosciences Inc has a 12 month low of $8.05 and a 12 month high of $26.55. The company has a current ratio of 5.46, a quick ratio of 5.46 and a debt-to-equity ratio of 1.84.
CHRS has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Citigroup reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Coherus Biosciences in a research note on Tuesday, November 7th. ValuEngine raised shares of Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. Finally, BidaskClub raised shares of Coherus Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Two analysts have rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $29.67.
Coherus Biosciences Company Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Want to see what other hedge funds are holding CHRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Coherus Biosciences Inc (NASDAQ:CHRS).
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.